Pfizer Secures Patent Extension for Vyndamax, Delaying Generic Competition
Pfizer has reached settlements with three generic drugmakers to extend the patent protection of Vyndamax, one of its best-selling drugs, through June 2031. This delay in generic competition provides Pfizer with additional time to develop new blockbuster drugs and stabilize its revenue. The deal is seen as positive for Pfizer's stock, with its shares rising 1.68% following the announcement.
Tickers: $PFE
Topics: generic drugs patent settlements Pfizer pharmaceuticals Vyndamax